Alpha-4 integrin-targeted monoclonal antibody therapy, which prevents lymphocyte trafficking across the blood-brain barrier, remains among the most efficacious therapies for relapsing-remitting multiple sclerosis (RRMS). Its benefit is counterbalanced by the risk of progressive multifocal leukoencephalopathy, stratified by anti-JCV antibody index, treatment duration, and prior immunosuppressant exposure.

A decade-spanning real-world cohort (104 RRMS patients; median follow-up 5.2 years) shows persistent seropositivity in 51.9%, seronegativity in 37.5%, and seroconversion of only 6.7%, with no PML cases. Treatment-naïve patients showed fewer relapses, lower MRI activity, and higher NEDA-3 rates (64.6% vs 32.7%) versus previously treated patients, confirming early high-efficacy therapy benefit. These real-world findings reinforce the value of sustained anti-JCV antibody index surveillance, extended-interval dosing consideration in high-index patients, and the benefit of early versus late high-efficacy therapy initiation. Neurologists and MS specialists managing RRMS will benefit from peer discussion of JCV surveillance strategies, benefit-risk optimization, and approaches to treatment duration and switching.

How do you incorporate anti-JCV antibody index trends into your long-term benefit-risk discussions, and at what threshold or pattern do you consider treatment modification or switching? What factors most influence your decision to initiate alpha-4 integrin antagonism as an early high-efficacy strategy versus a step-up approach in newly diagnosed or treatment-naïve RRMS patients?

Natalizumab, a humanized monoclonal antibody targeting alpha-4 integrin (VLA-4), prevents lymphocyte trafficking across the blood-brain barrier and remains among the most efficacious therapies for relapsing-remitting multiple sclerosis (RRMS). Its clinical benefit — including superior reductions in annualized relapse rate and MRI lesion burden — is counterbalanced by the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic CNS infection caused by JC virus (JCV) reactivation, stratified by anti-JCV antibody index, treatment duration, and prior immunosuppressant exposure.

A decade-spanning real-world cohort study comprising 104 RRMS patients followed for a median of 5.2 years provides longitudinal JCV serological data: persistent seropositivity in 51.9%, persistent seronegativity in 37.5%, and an overall seroconversion rate of only 6.7% — with no PML cases observed over the study period. Treatment-naive patients demonstrated significantly higher NEDA-3 rates (64.6% vs. 32.7%) versus previously treated patients, confirming established early high-efficacy therapy benefits. Complementary real-world and modeling data support extended-interval dosing (EID) — increasing infusion intervals from 4 to 6–8 weeks — as a strategy that preserves clinical efficacy while substantially reducing PML risk in anti-JCV antibody index-positive patients. EID represents a risk-mitigation approach that enables alpha-4 integrin antagonist continuation in patients who might otherwise require therapeutic switching, preserving superior disease control in high-efficacy responders.

How do you incorporate anti-JCV antibody index trends and extended-interval dosing strategies into your long-term alpha-4 integrin antagonist benefit-risk discussions, and at what index threshold or serological pattern do you recommend treatment modification or switching?

What factors most influence your decision to initiate alpha-4 integrin antagonism as an early high-efficacy strategy in newly diagnosed or treatment-naive RRMS patients, versus a sequentially escalated approach?